CeriBell, Inc. (CBLL) Insider Trading Activity

NASDAQ$27.8512-0.42 (-1.49%)
Market Cap
$1.08B
Sector
Healthcare
Industry
Medical—Devices
Rank in Sector
463 of 849
Rank in Industry
60 of 107

CBLL Insider Trading Activity

CBLL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$20,370,725
67
100

Related Transactions

Manni Joseph S.Chief Revenue Officer
0
$0
3
$72,694
$-72,694
ROBERTSON REBECCA Bdirector
0
$0
4
$183,232
$-183,232
Taylor Joseph Michaeldirector
0
$0
2
$407,678
$-407,678
Foehr DavidSenior VP, Finance and PAO
0
$0
11
$478,260
$-478,260
BURKE WILLIAM Wdirector
0
$0
2
$550,247
$-550,247
Blumberg ScottChief Financial Officer
0
$0
8
$1.39M
$-1.39M
Woo RaymondChief Technology Officer
0
$0
12
$1.68M
$-1.68M
Parvizi Josefdirector
0
$0
6
$2.12M
$-2.12M
TPG GP A, LLCFormer 10% Owner
0
$0
1
$4.07M
$-4.07M
Chao XingjuanPresident and CEO
0
$0
18
$9.42M
$-9.42M

About CeriBell, Inc.

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. …

Insider Activity of CeriBell, Inc.

Over the last 12 months, insiders at CeriBell, Inc. have bought $0 and sold $20.37M worth of CeriBell, Inc. stock.

On average, over the past 5 years, insiders at CeriBell, Inc. have bought $0 and sold $11.54M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

List of Insider Buy and Sell Transactions, CeriBell, Inc.

2026-10-01SaleWoo RaymondChief Technology Officer
4,887
0.0133%
$24.38
$119,145
+12.58%
2026-09-15SaleChao XingjuanPresident and CEO
20,846
0.0549%
$25.03
$521,775
-0.16%
2026-09-15SaleBlumberg ScottChief Financial Officer
846
0.0022%
$25.00
$21,150
-0.16%
2026-09-08SaleWoo RaymondChief Technology Officer
4,887
0.0129%
$24.33
$118,901
+2.26%
2026-09-08SaleFoehr DavidSenior VP, Finance and PAO
9,255
0.0243%
$24.25
$224,451
+2.26%
2026-09-02SaleChao XingjuanPresident and CEO
39,540
0.1034%
$24.61
$973,079
-0.36%
2026-09-02SaleBlumberg ScottChief Financial Officer
652
0.0017%
$25.00
$16,300
-0.36%
2026-08-24SaleFoehr DavidSenior VP, Finance and PAO
859
0.0023%
$23.95
$20,573
+2.51%
2026-08-21SaleChao XingjuanPresident and CEO
6,068
0.0158%
$24.02
$145,753
+1.28%
2026-08-21SaleWoo RaymondChief Technology Officer
1,979
0.0052%
$24.02
$47,536
+1.28%
2026-08-21SaleBlumberg ScottChief Financial Officer
1,521
0.004%
$24.02
$36,534
+1.28%
2026-08-21SaleManni Joseph S.Chief Revenue Officer
1,361
0.0036%
$24.02
$32,691
+1.28%
2026-08-21SaleFoehr DavidSenior VP, Finance and PAO
993
0.0026%
$24.02
$23,852
+1.28%
2026-08-19SaleChao XingjuanPresident and CEO
31,415
0.0833%
$25.03
$786,317
-1.57%
2026-08-19SaleBlumberg ScottChief Financial Officer
33,512
0.0888%
$25.03
$838,805
-1.57%
2026-08-18SaleChao XingjuanPresident and CEO
2,199
0.006%
$25.00
$54,975
+1.22%
2026-08-18SaleBlumberg ScottChief Financial Officer
990
0.0027%
$25.00
$24,750
+1.22%
2026-08-13SaleTaylor Joseph Michaeldirector
13,095
0.0347%
$23.40
$306,423
+4.99%
2026-08-03SaleChao XingjuanPresident and CEO
39,000
0.1036%
$18.32
$714,480
+32.93%
2026-07-07SaleChao XingjuanPresident and CEO
23,554
0.0622%
$19.90
$468,725
+20.63%
Total: 82
*Gray background shows transactions not older than one year

CBLL Institutional Investors: Active Positions

Increased Positions79+77.45%6M+22.79%
Decreased Positions45-44.12%4M-15.29%
New Positions38New3MNew
Sold Out Positions20Sold Out1MSold Out
Total Postitions136+33.33%28M+7.5%

CBLL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.